IRB Number:

1414-03

Trial Status:

Open for Enrollment

Phase: I

Why is this study being done?

This study is being done to learn about how and/or why Rituxan works in the body. It is designed to help to find out how cancer-fighting cells in the body move into the tumor before and after Rituxan is given

Who is Eligible to Participate in the Study?

Persons who will receive Rituxan antibody to treat their non-Hodgkin lymphoma may be eligible to participate in the study.

What is Involved With this Study?

Researcher will take blood from you once before Rituxan therapy and another time two days prior to the third cycle of Rituxan therapy. Your blood will be labeled with a special agent called Indium-111 (In-111), and then injected back into you. After that, we will take pictures using a special camera, called a gamma camera to see where the labeled cells go.

We will also use clinical information gathered the first 6 months after your Rituxan therapy for lymphoma (for example, blood tests, blood tests, and CT and other imaging scans).

How long will the Study run?

You will be followed for 6 months after you have stopped your Rituxan therapy.

Who can I Contact for Additional Information on this Trial?

Complete Request Form for Cancer Clinical Trial Information at Mayo Clinic or
For more information about this study or other clinical trial options, please contact our Mayo Clinic Cancer Center Clinical Trials Referral Office.

• Patients living within the United States, call 507-538-7623, or e-mail cancerclinicaltrials@mayo.edu


• Patients living outside the United States may call our International Office at 507-284-8884, or e-mail intl.mcr@mayo.edu.

What is/are the Locations of this Clinical Trial?

• Rochester, MN

Last updated: 03/28/2008